Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, et al. Blood 2022;139:1794-1806.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2022;139:1794-1806.
PMID: 34699592